IBSA (Institut Biochimique SA) was founded in 1945 in Lugano and acquired by the current owners in 1985, who completely redefined its vision and strategy.

From the late 1980s onward, after taking its first steps in the Swiss market, IBSA embarked on an exceptional and intensive development program, aiming to expand its assets and create a competitive product portfolio covering 10 therapeutic areas, including reproductive medicine, osteoarticular medicine, urogynecology, and aesthetic medicine.

IBSA products are now marketed on five continents and in over 90 countries. IBSA employs more than 2,500 people worldwide, spread across offices and production sites, and has 20 subsidiaries in Europe, China, and the United States.

The company is one of the largest global players in reproductive medicine and a world leader in hyaluronic acid-based products.